Skip to main navigation

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

News Releases

- Silverback - Investor Relations

Home
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly Results
IR Resources
- Email Alerts
- Contact IR

Year

Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference

10-05-2021

Silverback Therapeutics Presents Interim Clinical Results from the Ongoing Phase 1/1b Study of SBT6050 Alone or In Combination with Pembrolizumab in Patients with Advanced or Metastatic HER2-Expressing Solid Tumors

09-16-2021

Silverback Therapeutics to Present Data from its Phase 1/1b Clinical Trial of SBT6050 at the European Society for Medical Oncology (ESMO) 2021 Virtual Congress

09-13-2021

Silverback Therapeutics to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

09-07-2021

Silverback Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update

08-12-2021

Silverback Therapeutics to Participate in the 2021 Wedbush PacGrow Healthcare Conference

08-03-2021

Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers

07-07-2021

Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference

06-15-2021

Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

06-01-2021

Silverback Therapeutics Reports First Quarter 2021 Financial Results

05-13-2021

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 14

- Silverback - Investor Tools

Print Page
RSS Feeds
Email Alerts

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

© Copyright 2021 - Silverback Therapeutics^®